登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

San Diego's 'Godfather of biotech' discusses ins and outs of industry  

2008-10-05 17:02:12|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
DAVID F. HALE
David Hale is Chairman & CEO of Hale BioPharma Ventures, a private company focused on the
formation and development of biotechnology and specialty pharma companies. He is a co-founder and
currently serves as Executive Chairman and Interim CEO of Somaxon Pharmaceuticals. He was
previously President and CEO of CancerVax Corporation from October 2000 through May 2006, which
merged in May 2006 with Micromet, Inc., a biotechnology company focused on the development of
novel biological products for the treatment of cancer, when he became Chairman of the combined
companies.
Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a
number of biotechnology and specialty pharmaceutical companies. In 1982, after joining Hybritech,
Inc., the first monoclonal antibody company, he served as COO, President and then Chief Executive
Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997 he was
Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor,
Inc., which was acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene,
Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc. He was President and CEO of
Women First HealthCare, Inc. from late 1997 to June 2000, prior to joining CancerVax in October 2000.
Prior to joining Hybritech, Hale was Vice President and General Manager of BBL Microbiology
Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and
sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson,
Inc.
Mr. Hale is Chairman of the Board of Santarus, Inc., and Metabasis Therapeutics, Inc. which are
publicly held companies. He is a co-founder, Chairman and CEO of Neurelis, Inc. and serves as
Executive Chairman of privately held SkinMedica, Inc. and is a co-founder and director of Conatus
Pharmaceuticals Inc.
Mr. Hale also is a co-founder and serves on the Board of Directors of BIOCOM, is a member of the
Board of the Biotechnology Industry Organization (BIO) and the Biotechnology Institute. Hale also
serves on the Board of Directors of the San Diego Economic Development Corporation, the Burnham
Institute and Rady Children’s Hospital of San Diego. He is a co-founder of the CONNECT Program in
Technology and Entrepreneurship and currently serves as Chairman of the Board.
June 2008

David Hale is known as either a serial entrepreneur or, to some, as the “Godfather of biotech” due to his history of founding and developing more than 15 biotechnology and specialty pharmaceutical companies in San Diego County.
As founder, chairman and CEO of Hale BioPharma Ventures LLC, a private business focused on the start-up of biopharmaceutical companies, Hale has seen the region evolve into a biotechnology cluster.
During the “In the Executive’s Chair” course at California State University, San Marcos on Wednesday, Hale said his career in biotechnology and entrepreneurialism began with a move from Johnson & Johnson Inc. (NYSE: JNJ) in Baltimore to Hybritech Inc. in San Diego, where he would become CEO before its acquisition by Eli Lilly and Co. (NYSE: LLY).
When Hale came to Hybritech in the early 1980s, he wanted to grow the company quickly and aimed to promote within. In order to advance employees, Hale created a company culture of mentorship by giving people “the opportunities to do different things and groom them for additional responsibilities.”
Hale said former Hybritech employees have started more than 100 companies in San Diego.
Along with developing biotechnology companies, Hale said building organizations to support entrepreneurialism is important. He co-founded BIOCOM/San Diego while he was president and CEO of CancerVax after the city proposed shutting manufacturers’ water off for two to three hours a day as a result of the county’s drought.
Together with local CEOs, the group informed city and state levels about how the change would affect their businesses. Today Hale said BIOCOM/San Diego is an “environment for collaboration.”
As a board member for a number of organizations including Somaxon Pharmaceuticals Inc. (Nasdaq: SOMX) and Rady Children’s Hospital, Hale said members usually interact with the company only during board meetings.
The meetings are important “to focus on what’s really happening within the company, not just what’s happening well and good, but what are those critical issues that the company is facing in order to achieve success,” he said.
Hale continues in a search for new biotechnology developments. Next on his agenda is a company called Neurelis, which will focus on seizures experienced with epilepsy.
He also is an advocate for nanotechnology and believes a problem with many drugs is they are not orally volatile.
“One of the opportunities with nanotechnologies is to get nanoparticles out of those drugs … and make them orally active,” Hale said.
In regards to a business perspective on effective leadership qualities, he told students there are five attributions that make a great leader: a vision, mission, integrity, commitment and humility.
As Hale reflected on his time in the field, he applauds the county for developing products that are curing and treating patients, which were not previously available.
Hale said he is proud of what the biotechnology industry in San Diego has accomplished and “how it has impacted the world.”

  评论这张
 
阅读(317)| 评论(0)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018